Key takeaways
- Medical journals use the phrase; sections 503A and 503B of US drug law do not, and sort products by who made them, for whom, and what was checked first.
- FDA (page current as of 16 September 2025): “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
- Section 503A requires an identified individual patient and a valid prescription order; section 503B covers outsourcing facilities that register with FDA and follow current good manufacturing practice.
- In a notice filed on 28 October 2026, HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding with six named peptides in ten listed circumstances; the notice calls the policy a draft that is not binding, and it is not an approval.
01What is peptide therapy?
“Peptide therapy” is a phrase used in medical journals for treating patients with peptide drugs. A 2026 review in Sports Medicine applies it to “approved and unapproved” peptides alike. The two sections of US law behind this page, 503A and 503B, do not use the phrase. They sort a product by who made it, for whom, and what was checked first.
Three lanes matter for this page. Only the first two involve a prescription.
Approved medicine
A product FDA has approved for the uses on its label. FDA says people “rely on FDA’s drug approval process for verification of safety, effectiveness and quality”.
Compounded on prescription
A licensed pharmacist or physician combines, mixes or alters ingredients to make a medication for an individual patient. FDA: “Compounded drugs are not FDA-approved.”
Research use only
A product labelled for laboratory research. It is not made under section 503A or 503B, and FDA has not reviewed it for use in people.
This page describes US rules. The UK and Australia regulate differently: see the UK and Australia.
02What does “compounded” mean under sections 503A and 503B?
HHS’s notice of 30 October 2026 gives the definition. Compounding is “generally a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient”.
Section 503A covers a licensed pharmacist in a state-licensed pharmacy or federal facility, and a licensed physician. The drug must be compounded “for an identified individual patient based on the receipt of a valid prescription order”. When the section’s conditions are met, three requirements do not apply: FDA approval before marketing, labelling with adequate directions for use, and current good manufacturing practice (CGMP).
Section 503B covers outsourcing facilities, a category created in 2013. They register with FDA and stay subject to CGMP. The statute says an outsourcing facility “may or may not obtain prescriptions for identified individual patients”.
Who can prescribe. Section 503A refers to a prescription order “made by a licensed physician or other licensed practitioner authorized by State law to prescribe drugs”. State law decides which professions that covers.
Which ingredients. Under 503A, a bulk drug substance must comply with a USP or NF monograph, or be a component of an FDA-approved drug, or appear on a list FDA sets by regulation, the 503A bulks list. The interim categories FDA uses while it builds that list are on Category 1, 2 and 3.
| Route | Who makes it, and for whom | Reviewed by FDA before marketing? | Quality standard and oversight |
|---|---|---|---|
| Approved medicine | A manufacturer, for the patients and uses on the label | FDA: people “rely on FDA’s drug approval process for verification of safety, effectiveness and quality” | CGMP applies |
| Compounded, section 503A | A licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician, for an identified patient with a valid prescription | FDA: “Compounded drugs are not FDA-approved” | Exempt from CGMP when the section’s conditions are met. FDA: state boards of pharmacy “have primary responsibility for the day-to-day oversight” of these pharmacies |
| Compounded, section 503B | An outsourcing facility registered with FDA, which “may or may not obtain prescriptions for identified individual patients” | FDA: “Compounded drugs are not FDA-approved”; an outsourcing facility’s products are compounded drugs | CGMP applies. FDA: such facilities are “primarily overseen by FDA and inspected by FDA according to a risk-based schedule” |
| Research-use-only product | A seller, with labelling for laboratory research | Not reviewed for use in people | FDA judges intended use by “the objective intent of the persons legally responsible for the labeling”, shown for example by “labeling claims, advertising matter, or oral or written statements” (21 CFR 201.128) |
03Is peptide therapy FDA approved? What FDA says
FDA answers for the product, not for the phrase. In its words (page current as of 16 September 2025): “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
An approval belongs to one product and the uses on its label. Wegovy, for example, is a prescription medicine that contains the peptide semaglutide. Its US label covers, among other uses, reducing excess body weight in adults and children aged 12 and over with obesity, and in adults with overweight who have at least one weight-related condition, alongside a reduced-calorie diet and physical activity. Research-grade material sold under the same name is not that medicine.
The six peptides in HHS’s October 2026 draft policy (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500) are covered as bulk drug substances “not a component of an FDA-approved drug product”. The policy is about enforcement. It is not an approval.
04What changed in US peptide policy from 2023 to 2026?
- Sep 2023Category 2
FDA placed BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon in Category 2 of its interim list for 503A compounding, the category for substances that “may present significant safety risks”.
- 16–22 Apr 2026Nominations withdrawn, meeting announced
A Federal Register notice of 16 April announced an advisory committee meeting for 23 and 24 July. The six peptides’ time in Category 2 ended on 22 April; FDA’s page lists them as “withdrawn by the nominators”. HHS later wrote that “neither the placement nor the removal changed” their status under section 503A.
- 23–24 Jul 2026Advisory committee
FDA’s Pharmacy Compounding Advisory Committee discussed seven peptides. For the six above, HHS records that FDA’s drug centre “recommended against listing” and that the committee “voted in favor”. FDA describes such votes as “non-binding recommendations”. Detail: the 2026 advisory vote.
- 28–30 Oct 2026HHS draft policy
HHS said it “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding with one of the six, in ten listed circumstances. They include a patient-specific prescription and a single active ingredient. The notice, filed on 28 October and published on 30 October, calls the policy a draft that “is not binding on HHS or the public”. Detail: the HHS policy, explained.
- NextRulemaking
The policy applies until a peptide “is addressed in a final rule as being included or not included on the 503A bulks list”. HHS says it may revisit the interim policy “if, among other things, a safety signal or product quality issue arises”. Dated updates: regulatory changelog.
05Is peptide therapy safe? What regulators say
Each statement below is about one route, in the regulator’s own words, with its date. None is a judgement about a particular patient.
Approved medicines. Safety information is part of the approved label. Wegovy’s label, for example, carries a boxed warning: semaglutide causes thyroid C-cell tumours in rodents, and “It is unknown whether WEGOVY causes thyroid C-cell tumors” in humans (label effective 18 June 2026).
Compounded drugs. FDA (page current as of 16 September 2025): “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” It adds that poor compounding practices “can result in serious drug quality problems” and that this “can lead to serious patient injury and death”. For compounded versions of two approved peptide medicines, FDA had received 990 adverse-event reports for semaglutide and more than 730 for tirzepatide as of 31 May 2026. FDA attaches three limits to those figures: reports are likely under-counted, because state-licensed pharmacies that are not outsourcing facilities are not required to submit them; many appear consistent with events seen with the approved products; and it is “not always possible to determine if the adverse event directly resulted from use of the drug”.
BPC-157, one of the six peptides in HHS’s draft policy. FDA staff’s July 2026 review found “insufficient clinical safety information to characterize the safety profile”, and said that as a peptide “administered through a parenteral or nasal” route it “may pose a significant risk for immunogenicity”. FDA’s compounding page (current as of 22 April 2026) says of BPC-157 that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans”. HHS’s policy text says the policy “advances patient choice and freedom while appropriately protecting patient safety”, and it has compounders report serious adverse events to FDA.
Research-use-only products. HHS’s policy text names one aim as to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients”. FDA says it has warned companies that “illegally sold” unapproved GLP-1 drugs “falsely labeled ‘for research purposes’ or ‘not for human consumption’” directly to consumers, and describes those products as “of unknown quality” that “may be harmful to their health” (page current as of 1 October 2026).
More: are peptides safe and peptide side effects.
06What does a regulator check on each route?
The routes differ in what is checked, by whom, and when.
Approved medicine: the product.
Before marketing, FDA’s approval process verifies safety, effectiveness and quality for the uses on the label.
Section 503A: the prescription and the licence.
An identified patient, a valid prescription, and a licensed pharmacist or physician. State boards of pharmacy have primary day-to-day oversight.
Section 503B: the facility.
Registration with FDA, CGMP, and FDA inspection on a risk-based schedule. The products are still compounded drugs, which are not FDA-approved.
Research use only: the intended use.
FDA looks at “the objective intent” of whoever is responsible for the labelling, shown by claims, advertising and statements. More: what “research use only” means.
What we don’t know.
- Whether FDA will add any of the six peptides to the 503A bulks list. HHS’s notice says future rulemakings “may propose adding some or all of these peptides”.
- How long the interim policy will stand. HHS says it may revisit it, in whole or in part.
How evidence differs between approved and unapproved peptides: do peptides work? and peptides graded by evidence. Rule changes, once a week: the 6:00 brief.
This is a plain-English summary of public documents, checked on 21 Nov 2026. It is not legal or medical advice.